Currently, there are 204.94M common shares owned by the public and among those 165.06M shares have been available to trade.
The company’s stock has a 5-day price change of 39.06% and 16.34% over the past three months. TSHA shares are trading 2.89% year to date (YTD), with the 12-month market performance down to -26.14% lower. It has a 12-month low price of $1.05 and touched a high of $4.32 over the same period. TSHA has an average intraday trading volume of 2.08 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 27.05%, 13.56%, and -7.82% respectively.
Institutional ownership of Taysha Gene Therapies Inc (NASDAQ: TSHA) shares accounts for 77.23% of the company’s 204.94M shares outstanding.
It has a market capitalization of $365.00M and a beta (3y monthly) value of 0.87. The earnings-per-share (ttm) stands at -$0.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.10% over the week and 13.92% over the month.
Analysts forecast that Taysha Gene Therapies Inc (TSHA) will achieve an EPS of -0.1 for the current quarter, -0.09 for the next quarter and -0.39 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.1 while analysts give the company a high EPS estimate of -0.1. Comparatively, EPS for the current quarter was -0.1 a year ago. Earnings per share for the fiscal year are expected to decrease by -0.23%, and -21.78% over the next financial year. EPS should grow at an annualized rate of 7.82% over the next five years, compared to -63.99% over the past 5-year period.
Looking at the support for the TSHA, a number of firms have released research notes about the stock. BMO Capital Markets stated their Outperform rating for the stock in a research note on June 27, 2024, with the firm’s price target at $5. Piper Sandler coverage for the Taysha Gene Therapies Inc (TSHA) stock in a research note released on April 09, 2024 offered a Overweight rating with a price target of $9. Jefferies was of a view on February 01, 2023 that the stock is Hold, while Morgan Stanley gave the stock Equal-Weight rating on January 27, 2023, issuing a price target of $23- $3. Goldman on their part issued Neutral rating on November 09, 2022.
